What this study is
The goal of this clinical trial is to learn if the use of rapamycin cream can be used as a treatment together with pulsed dyed laser in treating port wine stain birthmarks. The main question it aims to answer is:
Will rapamycin cream and laser treatment show a greater improvement in appearance of port wine birthmarks, compared to treatment with placebo cream and laser?
Researchers will compare two concentrations of rapamycin cream (0.6% or 1.0%) with placebo treatment to see if appearance is improved following 12 weeks of treatment.
Participants will receive laser treatment of their port wine birthmark and then apply the rapamycin or placebo cream daily for 12 weeks. Patients will visit the clinic every 4 weeks for checkups and tests.
What's being tested
- Rapamycin cream
Intervention · DRUG
Application of rapamycin cream to port wine birthmark
- Pulsed dyed laser
Intervention · PROCEDURE
Pulsed dyed laser (PDL) treatment of port wine birthmark
Study details
- Official title
- Rapamycin Dose-Ranging Efficacy Study: A Phase II, Proof of Concept, Double-blind, Placebo-controlled, Randomized, Parallel-group, Dose-response Comparison of the Effects of Different Strengths of Rapamycin Cream Applied Topically in Subjects Diagnosed With Port Wine Stains
- Sponsor
- AFT Pharmaceuticals, Ltd.
- Conditions
- Port Wine Stains
- Enrolling
- 30 people
- Starts
- 2026-11-13
- Est. completion
- 2027-10
- Design
- Quadruple-blind, randomized, parallel groups, Phase 2
- Record
- View on ClinicalTrials.gov ↗
Who can join
Age Up to 10 YearsSex ALLHealthy volunteers Not acceptedYou may qualify if
- Male and female patients aged ≤ 10 years on the day informed consent is obtained
- Patients presenting either facial, neck, or upper trunk port-wine stains
- Port wine stain size of at least 5 cm tall x 2.5 cm wide (2x1 inches)
- Patients (or their legal representatives) capable of understanding the explanation of the clinical trial, and who give written informed consent for participation
- Patients (or their legal representatives) able to maintain patient diaries following the instructions of the investigator or sub-investigator
- Patients (or their guardians) are willing and able to follow instructions to only apply cream to part of their port-wine stain
- Skin type classified as either I, II, III or IV on the Fitzpatrick scale
- Patients who are indicated for PDL treatment and accept this treatment
- Patients who respond to PDL with purpura or blanching
You can't join if
- Skin type classified as either V or VI on the Fitzpatrick scale
- Patients with PWS in extremities and/or acral areas
- Patients unwilling or unable to carry out the treatment plan or follow-up assessment
- Patients with serious skin lesions such as erosions or ulcers
- Patients with known hypersensitivity to any component of the study product
- Patients who have received rapamycin/sirolimus, everolimus, or temsirolimus within 3 months of enrolment
- Patients who have received laser therapy or surgical therapy to treat PWS within 3 months prior to trial enrolment
- Patients who have received 5 or more PDL treatments previously
- Patients who participated in any other clinical trial within 3 months prior to the day of enrolment
- Patients judged unsuitable for this clinical trial by the investigator or sub-investigator
- Pregnant or lactating females
- Sexually active females of childbearing potential not using adequate contraception and sexually active males not using adequate contraception*
- Patients with immune dysfunction or receiving any form of immunosuppression
Sign in and we'll check these against your records.Full criteria on ClinicalTrials.gov ↗
Loading treatment details…
Study locations (2)
2 openDriscoll Children's Hospital
Corpus Christi, Texas, United States
- Erin Richmond, MS, RN, CCRP · Contact361-694-5978erin.richmond@dchstx.org
- Denise Metry, MD · Principal investigator
1 site outside the US
Sant Joan de Déu University Hospital
Barcelona, Catalonia, Spain
- Study Coordinator - Unitat d'Investigacio Clinica · Contact+34 670989833mateu.torres@sjd.es
- Marta Ivars, MD · Principal investigator
Study team
Sponsor
AFT Pharmaceuticals, Ltd.
Study ID AFT-RAP-01
Study director
Ioana Stanescu
AFT Pharmaceuticals
Frequently asked questions
The sponsor hasn't published answers to common questions for this trial.